[Current Topics in Microbiology and Immunology] Therapeutic Kinase Inhibitors Volume 355 || JAK-Mutant Myeloproliferative Neoplasms

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Phosphoinositide 3-kinase in Health and Disease Volume 347 || Small Molecule Inhibitors of the PI3-Kinase Family

✍ Rommel, Christian; Vanhaesebroeck, Bart; Vogt, Peter K. 📂 Article 📅 2010 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 327 KB

PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost inva

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Phosphoinositide 3-kinase in Health and Disease Volume 347 || From the Bench to the Bed Side: PI3K Pathway Inhibitors in Clinical Development

✍ Rommel, Christian; Vanhaesebroeck, Bart; Vogt, Peter K. 📂 Article 📅 2010 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 377 KB

PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost inva

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Phosphoinositide 3-kinase in Health and Disease Volume 347 || New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)

✍ Rommel, Christian; Vanhaesebroeck, Bart; Vogt, Peter K. 📂 Article 📅 2010 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 321 KB

PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost inva